Ricochet is the best place on the internet to discuss the issues of the day, either through commenting on posts or writing your own for our active and dynamic community in a fully moderated environment. In addition, the Ricochet Audio Network offers over 50 original podcasts with new episodes released every day.
Since again the “news” media do such a terrible job of reporting facts, I’m turning to the knowledgeable people of Ricochet.
Is the monoclonal antibody treatment for which the Food and Drug Administration recently revoked emergency-use authorization the only monoclonal antibody treatment that was available to the public? In other words, did the FDA’s revocation stop all monoclonal antibody treatments for people who get COVID-19 or only some? The news media is interested only in reporting the politicians yelling at each other, not on any underlying facts.
I had been hearing many anecdotal stories about favorable results from monoclonal antibody treatments. Among the anecdotes, two friends of mine who recently (two weeks ago) tested positive for COVID-19 received monoclonal antibody treatments, and their conditions immediately improved significantly. Of course, the experience of two of my friends is not scientific proof of anything, and we can’t even be certain that the treatment caused the improvement of my two friends — though for one in particular, the coincidence of treatment and the magnitude of improvement was remarkable. Nor do I know if their treatments were the same ones for which the FDA revoked emergency-use authorization.
The closing of Florida treatment centers and accompanying yelling by Florida Gov. Ron DeSantis gives the impression that all monoclonal antibody treatments have been stopped. But maybe Florida was using only one version, the version that was the subject of the FDA action.
I admit that I come into this discussion with a bias, as it seems to me that the FDA and the Centers for Disease Control and Prevention are focused on vaccines for COVID-19 and are generally opposed to (or at least uninterested in) finding treatments for those who become infected. That anti-treatment bias may not be true, but abruptly revoking the emergency-use authorization of monoclonal antibodies without much further detailed explanation provides fuel for the speculation that the agencies are anti-treatment. More information on the scope of the FDA’s action would help the not-medically-trained me evaluate what’s going on.
So, did the FDA’s revocation of emergency-use authorization for monoclonal antibody treatments apply to only some treatments or to all of the monoclonal antibody treatments that people had been getting? Do people who have COVID-19 still have an option to receive monoclonal antibody treatment, or are all options to receive monoclonal antibody treatment off the table?Published in